Le Lézard
Classified in: Business
Subject: ATY

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Wins Finance Holdings Inc. - WINS

NEW YORK, July 9, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Wins Finance Holdings Inc. ("Wins" or the "Company") (NASDAQ: WINS).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Wins and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On July 6, 2020, Wins disclosed that on June 30, 2020, Centurion ZD CPA & Co. resigned as the Company's independent auditor. 

On this news, Wins' stock price fell $2.06 per share, or 6.1%, to close at $31.70 per share on July 7, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Robert S. Willoughby
Pomerantz LLP
888-476-6529 ext. 7980

SOURCE Pomerantz LLP

These press releases may also interest you

at 16:05
Acorda Therapeutics, Inc. today provided a business update and reported its financial results for the second quarter ended June 30, 2020. "We were pleased with INBRIJA's performance in the second quarter, especially in light of the significant...

at 16:05
Enanta Pharmaceuticals, Inc. , a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal third quarter ended June 30, 2020. "During the...

at 16:05
Vapotherm, Inc. , ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory...

at 16:05
Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2020 and provided a...

at 16:05
Avalara, Inc. , a leading provider of tax compliance automation for businesses of all sizes, today announced financial results for its second quarter ended June 30, 2020. "Avalara posted a strong second quarter, exceeding our guidance, with June...

at 16:05
Cerus Corporation today announced financial results for the second quarter ended June 30, 2020. Recent developments and highlights include: Q2 2020 Total Revenue of $26.8 million - driven by robust year-over-year platelet kit sales growth in...

News published on 9 july 2020 at 19:40 and distributed by: